These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 24010644)

  • 1. All-oral therapy with nucleotide inhibitors sofosbuvir and GS-0938 for 14 days in treatment-naive genotype 1 hepatitis C (nuclear).
    Lawitz EJ; Rodriguez-Torres M; Denning J; Mathias A; Mo H; Gao B; Cornpropst MT; Berrey MM; Symonds WT
    J Viral Hepat; 2013 Oct; 20(10):699-707. PubMed ID: 24010644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-naïve patients with HCV genotype 1: a randomized, 28-day, dose-ranging trial.
    Rodriguez-Torres M; Lawitz E; Kowdley KV; Nelson DR; Dejesus E; McHutchison JG; Cornpropst MT; Mader M; Albanis E; Jiang D; Hebner CM; Symonds WT; Berrey MM; Lalezari J
    J Hepatol; 2013 Apr; 58(4):663-8. PubMed ID: 23183528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of hepatitis C viral kinetics during administration of two nucleotide analogues: sofosbuvir (GS-7977) and GS-0938.
    Guedj J; Pang PS; Denning J; Rodriguez-Torres M; Lawitz E; Symonds W; Perelson AS
    Antivir Ther; 2014; 19(2):211-20. PubMed ID: 24464551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: an open-label, phase 3 trial.
    Omata M; Nishiguchi S; Ueno Y; Mochizuki H; Izumi N; Ikeda F; Toyoda H; Yokosuka O; Nirei K; Genda T; Umemura T; Takehara T; Sakamoto N; Nishigaki Y; Nakane K; Toda N; Ide T; Yanase M; Hino K; Gao B; Garrison KL; Dvory-Sobol H; Ishizaki A; Omote M; Brainard D; Knox S; Symonds WT; McHutchison JG; Yatsuhashi H; Mizokami M
    J Viral Hepat; 2014 Nov; 21(11):762-8. PubMed ID: 25196837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study.
    Curry MP; Forns X; Chung RT; Terrault NA; Brown R; Fenkel JM; Gordon F; O'Leary J; Kuo A; Schiano T; Everson G; Schiff E; Befeler A; Gane E; Saab S; McHutchison JG; Subramanian GM; Symonds WT; Denning J; McNair L; Arterburn S; Svarovskaia E; Moonka D; Afdhal N
    Gastroenterology; 2015 Jan; 148(1):100-107.e1. PubMed ID: 25261839
    [TBL] [Abstract][Full Text] [Related]  

  • 6. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study.
    Nelson DR; Cooper JN; Lalezari JP; Lawitz E; Pockros PJ; Gitlin N; Freilich BF; Younes ZH; Harlan W; Ghalib R; Oguchi G; Thuluvath PJ; Ortiz-Lasanta G; Rabinovitz M; Bernstein D; Bennett M; Hawkins T; Ravendhran N; Sheikh AM; Varunok P; Kowdley KV; Hennicken D; McPhee F; Rana K; Hughes EA;
    Hepatology; 2015 Apr; 61(4):1127-35. PubMed ID: 25614962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Phase I, randomized, placebo-controlled, 3-day, ascending-dose study of GS-9451, an NS3/4A protease inhibitor, in genotype 1 hepatitis C patients.
    Lawitz EJ; Hill JM; Marbury T; Demicco MP; Delaney W; Yang J; Moorehead L; Mathias A; Mo H; McHutchison JG; Rodriguez-Torres M; Gordon SC
    Antivir Ther; 2013; 18(3):311-9. PubMed ID: 23047118
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sofosbuvir as backbone of interferon free treatments.
    Bourlière M; Oules V; Ansaldi C; Adhoute X; Castellani P
    Dig Liver Dis; 2014 Dec; 46 Suppl 5():S212-20. PubMed ID: 25453869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rapid HCV-RNA decline with once daily TMC435: a phase I study in healthy volunteers and hepatitis C patients.
    Reesink HW; Fanning GC; Farha KA; Weegink C; Van Vliet A; Van 't Klooster G; Lenz O; Aharchi F; Mariën K; Van Remoortere P; de Kock H; Broeckaert F; Meyvisch P; Van Beirendonck E; Simmen K; Verloes R
    Gastroenterology; 2010 Mar; 138(3):913-21. PubMed ID: 19852962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ledipasvir + sofosbuvir (Harvoni). A therapeutic advance in genotype 1 hepatitis C virus infection, despite uncertainties.
    Prescrire Int; 2015 Dec; 24(166):285-9. PubMed ID: 26788571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overall efficacy and safety results of sofosbuvir-based therapies in phase II and III studies.
    Mangia A; Piazzolla V
    Dig Liver Dis; 2014 Dec; 46 Suppl 5():S179-85. PubMed ID: 25458780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GS-9857 in patients with chronic hepatitis C virus genotype 1-4 infection: a randomized, double-blind, dose-ranging phase 1 study.
    Rodriguez-Torres M; Glass S; Hill J; Freilich B; Hassman D; Di Bisceglie AM; Taylor JG; Kirby BJ; Dvory-Sobol H; Yang JC; An D; Stamm LM; Brainard DM; Kim S; Krefetz D; Smith W; Marbury T; Lawitz E
    J Viral Hepat; 2016 Aug; 23(8):614-22. PubMed ID: 26957110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection.
    Everson GT; Sims KD; Rodriguez-Torres M; Hézode C; Lawitz E; Bourlière M; Loustaud-Ratti V; Rustgi V; Schwartz H; Tatum H; Marcellin P; Pol S; Thuluvath PJ; Eley T; Wang X; Huang SP; McPhee F; Wind-Rotolo M; Chung E; Pasquinelli C; Grasela DM; Gardiner DF
    Gastroenterology; 2014 Feb; 146(2):420-9. PubMed ID: 24184132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of sofosbuvir-based therapy for the treatment of chronic hepatitis C in treatment-naïve and treatment-experienced patients.
    Liu X; Wang Y; Zhang G; Li N; Zhu Q; Chang H; Han Q; Lv Y; Liu Z
    Int J Antimicrob Agents; 2014 Aug; 44(2):145-51. PubMed ID: 25034873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial.
    Osinusi A; Meissner EG; Lee YJ; Bon D; Heytens L; Nelson A; Sneller M; Kohli A; Barrett L; Proschan M; Herrmann E; Shivakumar B; Gu W; Kwan R; Teferi G; Talwani R; Silk R; Kotb C; Wroblewski S; Fishbein D; Dewar R; Highbarger H; Zhang X; Kleiner D; Wood BJ; Chavez J; Symonds WT; Subramanian M; McHutchison J; Polis MA; Fauci AS; Masur H; Kottilil S
    JAMA; 2013 Aug; 310(8):804-11. PubMed ID: 23982366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sofosbuvir (GS-7977), a pan-genotype, direct-acting antiviral for hepatitis C virus infection.
    Rodríguez-Torres M
    Expert Rev Anti Infect Ther; 2013 Dec; 11(12):1269-79. PubMed ID: 24215243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapid decline of viral RNA in chronic hepatitis C patients treated once daily with IDX320: a novel macrocyclic HCV protease inhibitor.
    de Bruijne J; van Vliet A; Weegink CJ; Mazur W; Wiercinska-Drapało A; Simon K; Cholewińska-Szymańska G; Kapocsi J; Várkonyi I; Zhou XJ; Temam MF; Molles J; Chen J; Pietropaolo K; McCarville JF; Sullivan-Bólyai JZ; Mayers D; Reesink H
    Antivir Ther; 2012; 17(4):633-42. PubMed ID: 22427481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sofosbuvir for the treatment of chronic hepatitis C virus infection.
    Temesgen Z; Talwani R; Rizza SA
    Drugs Today (Barc); 2014 Jun; 50(6):421-34. PubMed ID: 24983590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sofosbuvir, a novel nucleotide analogue inhibitor used for the treatment of hepatitis C virus.
    Summers BB; Beavers JW; Klibanov OM
    J Pharm Pharmacol; 2014 Dec; 66(12):1653-66. PubMed ID: 25175944
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessing safety and efficacy of sofosbuvir for the treatment of hepatitis C.
    D'Ambrosio R; Aghemo A; Colombo M
    Expert Opin Drug Saf; 2015 Mar; 14(3):473-84. PubMed ID: 25645644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.